Diaprel

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Diaprel

Property Description
Active ingredient Gliclazide
Form Tablet (Modified Release)
Pharmacological class Oral Hypoglycemic Agent (OHA)
Common use Management of Type 2 Diabetes Mellitus
Origin Synthetic (Second-generation sulfonylurea)

What is Diaprel (Gliclazide) and Its Primary Classification?

Diaprel is the trade name for the active pharmaceutical ingredient (INN) Gliclazide, which is broadly classified as an Oral Hypoglycemic Agent (OHA), a category of synthetic medicine used for the systemic management of high blood sugar in adults with Type 2 Diabetes Mellitus. Gliclazide is utilized for its therapeutic application in this condition.

Gliclazide belongs to the therapeutic group known as sulfonylureas, functioning as antidiabetic agents taken by mouth for peroral administration. This classification confirms its role as a necessary medication for metabolic control. Diaprel is consistently supplied as a prescription-only medicine (POM).

Composition, Form, and Therapeutic Grouping

The active substance, Gliclazide, is a synthetic sulfonylurea derivative, specifically recognized as a second-generation sulfonylurea based on its refined chemical structure. This chemical grouping represents an established approach to glucose regulation.

The drug is delivered as a single-ingredient product, most often manufactured as a tablet. This solid oral dosage matrix frequently utilizes a modified release (MR) tablet formulation. The MR formulation is a key differentiating feature, engineered to control the rate at which Gliclazide is released into the system, contributing to stable, consistent therapeutic action throughout the day.

Gliclazide's Essential Action: An Insulin Secretagogue

The essential physiological action that defines Gliclazide is its function as an insulin secretagogue. The primary purpose of this action is to lower blood glucose levels. This mechanism works by causing the functioning pancreatic beta-cells to release more of the body’s naturally produced insulin. By augmenting the endogenous insulin supply, the drug provides a highly targeted therapeutic approach to manage the deficit in insulin secretion that characterizes the progression of Type 2 Diabetes Mellitus, thereby contributing to effective blood glucose balance.

What side effects are possible with Diaprel?

Possible Side Effects and Safety Information

The safety profile of Gliclazide (Diaprel), a sulfonylurea, is primarily defined by the risk of hypoglycaemia (low blood sugar), which is officially classified as a Common adverse reaction in regulatory documents and results from the drug's action of increasing insulin release.

Adverse Reaction Classifications

Side effects are classified by frequency and grouped into System-Organ Classes (SOC) as follows:

  • Common Reactions: Hypoglycaemia is the most frequent adverse event. The risk of hypoglycaemia is officially stated to be higher at the start of treatment or during dose escalation.
  • Uncommon Reactions: These include Gastrointestinal Disorders such as abdominal pain, nausea, vomiting, diarrhoea, and constipation.
  • Rare Reactions: These involve more systemic effects, including changes in haematology (e.g., leucopenia, thrombocytopenia) and Hepatobiliary Disorders such as hepatitis and elevated hepatic enzyme levels. Skin reactions ( rash, pruritus) are also documented in this range.

Serious Adverse Reactions and Safety Constraints

The official labeling documents rare but clinically significant adverse reactions, including severe forms of hypoglycaemia, severe bullous skin reactions (e.g., Stevens-Johnson Syndrome), and severe haematological disorders ( agranulocytosis).

Safety Restrictions (Contraindications): Gliclazide is contraindicated in patients with severe renal or hepatic insufficiency, as these conditions significantly increase the risk and severity of hypoglycaemia. The medication is also contraindicated in Type 1 diabetes, diabetic keto-acidosis, and diabetic pre-coma/coma.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose with Diaprel (Gliclazide) primarily results in excessive lowering of blood glucose, a state known as hypoglycaemia. Officially documented manifestations range from moderate symptoms correctable with carbohydrate intake to severe hypoglycaemic reactions, which include convulsions, coma, or other neurological disorders. Symptoms such as anxiety, tachycardia, and clammy skin may also be present as signs of the body’s counter-regulation.


Required Emergency Actions

Immediate medical attention and hospitalisation are required for all severe reactions or any episode determined to be prolonged. Even if initial carbohydrate intake provides temporary relief, severe or persistent low blood sugar mandates urgent medical evaluation. The required procedural steps for managing coma involve a rapid I.V. injection of concentrated glucose solution, followed by a continuous infusion with strict targets for stabilizing blood sugar. Strict monitoring must be maintained until the patient is officially out of danger. Regulatory documents state that dialysis is of no benefit and no specific antidote is known.


Susceptible Populations

Specific populations face an increased risk of a severe or prolonged episode. Regulatory documentation indicates that patients with severe renal insufficiency or severe hepatic insufficiency, as well as elderly subjects, are particularly susceptible to severe hypoglycaemia following an overdose.

Therapeutic Uses of Diaprel

What Diaprel Treats: Main Uses and Benefits

Diaprel (Gliclazide) is commonly used for the long-term management of Type 2 Diabetes Mellitus in adults when lifestyle changes are insufficient to achieve metabolic control. It is applied across therapeutic domains where additional support for systemic imbalance is needed, contributing to easing the overall symptom load of the disease. The medication is categorized as a treatment for non-insulin dependent diabetes.

A primary therapeutic action is addressing persistent hyperglycemia, along with managing high HbA1c and postprandial glucose spikes. Diaprel is therefore relevant for easing groups of symptoms associated with metabolic strain. By helping to normalize blood sugar levels, Diaprel contributes to long-term patient benefit by providing therapeutic support that helps mitigate the risk of serious long-term complications. It extends treatment support to patient groups like adults who retain sufficient pancreatic function to benefit from this class of medication.

The medication is commonly relevant in contexts where the patient's diabetes is suboptimally controlled or when initial single-drug treatments are insufficient to meet glycemic goals. The goal of therapy is to help with maintaining functional stability and supporting the patient's general well-being.


Quick Fact: Relief for Metabolic Imbalance
Diaprel is used to address the chronic problem of hyperglycemia and helps manage the resulting physiological strain caused by high sugar levels.

Eligibility and Restrictions for Use

Who Can and Cannot Use Diaprel?

Diaprel (Gliclazide) is officially restricted to use in adults diagnosed with Type 2 Diabetes Mellitus. Eligibility is strictly defined by regulatory bodies through specific contraindications and population restrictions.

Populations Who Must Not Use Diaprel (Contraindicated)

Use of Gliclazide is contraindicated (absolutely prohibited) for several groups, including:

  • Patients with Insulin-dependent diabetes mellitus (Type 1 Diabetes).
  • Individuals with known hypersensitivity to gliclazide, other sulfonylureas, or sulfonamides.
  • Patients experiencing diabetic keto-acidosis or diabetic coma.
  • Individuals with severe hepatic insufficiency or severe renal insufficiency.
  • Women who are pregnant or lactating (breastfeeding).
  • Patients using systemic Miconazole.

Restricted and Non-Recommended Use

Population Group Regulatory Status
Children and Adolescents Not recommended; safety and effectiveness have not been established.
Mild/Moderate Impairment Requires conditional use and careful monitoring in mild to moderate renal or hepatic insufficiency.
Older Adults Approved for use, often utilizing the same general dosing guidelines as younger adults.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile for Diaprel (Gliclazide) is governed by its action as an Oral Hypoglycemic Agent, with official regulatory documentation classifying combinations based on their risk of altering blood sugar control. All interaction information is derived from government-approved prescribing information.

Formally Contraindicated and Not Recommended Combinations

Co-administration with Miconazole (systemic or oromucosal gel) is contraindicated due to the severe risk of potentiating the drug's effect, which can lead to profound hypoglycemia. Furthermore, alcohol is not recommended as it inhibits the body's compensatory mechanisms for low blood sugar, carrying a risk of hypoglycemic coma. The NSAID Phenylbutazone (systemic route) and the hormonal agent Danazol are also generally not recommended combinations.

Modifications to Blood Sugar Control

Many substances are classified as requiring precautions for use because they modify Gliclazide's action. Medicines that potentiate the blood glucose-lowering effect (risk of hypoglycemia) include other Antidiabetic Agents, ACE Inhibitors, Beta-blockers, and certain antibiotics like Fluconazole. Conversely, agents that can cause a hyperglycemic action (risk of reduced efficacy) include Glucocorticoids and Beta-2 Agonists.

Pharmacokinetic and Population Considerations

The regulatory label notes that the herbal product St. John's Wort is cautioned against, as it can decrease Gliclazide’s systemic exposure (clearance), potentially leading to a loss of blood sugar control. The risk of severe hypoglycemic reactions is officially noted to be increased in patients with severe hepatic or renal impairment.

Mechanism of Action

Diaprel is a sulfonylurea compound that induces a decrease in plasma glucose concentration via two primary mechanisms.

First, the compound acts on the pancreas to enhance insulin secretion. It achieves this by binding specifically to the SUR1 subunit of the K ATP channel located on the pancreatic beta-cell membrane. This interaction inhibits the K ATP channel, leading to the depolarization of the beta-cell membrane. The resulting depolarization opens voltage-dependent Ca^2+ channels, facilitating an influx of Ca^2+ ions, which subsequently triggers the exocytosis and release of insulin from the beta-cells.

Second, Diaprel exerts an extra-pancreatic effect by increasing insulin sensitivity in peripheral tissues. This action modulates insulin receptor signaling and metabolic enzyme activity, resulting in enhanced glucose uptake and utilization by muscle and adipose tissues.

Dosage and Administration Information

How to Use Diaprel

Diaprel (Gliclazide Modified Release) is an oral hypoglycemic agent used as part of a long-term treatment plan for managing Type 2 Diabetes Mellitus. The administration protocol is established to ensure the medicine's intended modified-release action is maintained.


Official Administration Guidelines

Instruction Detail
Route of administration: Oral use (Peroral administration).
Dosing schedule: The usual starting dose for adults is 30 mg once daily. The dose can be adjusted to a maximum of 120 mg daily, taken as a single intake.
Timing in relation to meals: The tablet(s) must be taken at breakfast time (with food).
Preparation requirements: The modified-release tablet(s) must be swallowed whole with water and must not be crushed or chewed.
Age-group administration rules: Older Adults (ge 65 years): The dosage regimen is the same as for the general adult population, starting with 30 mg daily.
Missed-dose rules: If a dose is missed, do not take a double dose the next day; the next dose is taken at the usual time.

Procedural Structure and Adjustment Logic

Administration is structured as a single daily intake, which is explicitly tied to the morning meal. This simple frequency pattern supports long-term adherence to the regimen. Dose adjustments are performed in increments of 30 mg based on clinical response, with the interval between increments typically being at least one month. However, if blood glucose is not adequately controlled after the initial two weeks of treatment, an increase may be considered at the end of the second week. These guidelines define the full procedural steps for initiating and managing the prescribed use of Gliclazide Modified Release.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Diaprel (Gliclazide)

This overview summarizes the available clinical research that defines the evidence base for Diaprel (Gliclazide modified-release). It describes the types of studies conducted, the outcomes they monitored, and where research limitations or uncertainties may still exist.


Evidence for Core Glycemic Control in Type 2 Diabetes

Research examining Diaprel's use for glycemic control was evaluated in Randomized Controlled Trials (RCTs) and Systematic Reviews focused on adults diagnosed with Type 2 Diabetes Mellitus (T2DM). These studies were applied in research contexts involving fluctuating blood sugar levels where better daily management was needed.

Researchers primarily studied the change in biomarkers, notably Glycated Hemoglobin ( HbA1c) and Fasting Plasma Glucose (FPG), which are used to monitor blood sugar status over time. Findings were observed across many studies examining this use, and the evidence contributes to understanding symptom patterns.


Research on Long-Term Outcomes and Vascular Events

A large-scale, long-term RCT, known as the ADVANCE trial, was conducted to explore patterns of outcomes related to vascular complications in T2DM patients. The trial included over 11,000 middle-aged and older adults.

Researchers focused on an intensive glucose control strategy that used Gliclazide modified-release as the core drug. Outcomes monitored included the frequency of major microvascular events (such as kidney disease) and macrovascular events (such as heart attack or stroke).

The trial monitored outcomes and reported measurements of the composite microvascular and macrovascular outcome when compared to the standard control group. Findings describe group patterns related to the intensive treatment strategy, not personal outcomes from Diaprel as a single agent.

What remains uncertain is the long-term effect of Diaprel alone, as the specific cardiovascular findings do not independently define its long-term benefit. Comparative evidence is lacking from dedicated trials structured to examine these specific long-term cardiovascular outcomes.


Evidence Comparing Diaprel to Other Treatments

Systematic Reviews and Meta-analyses were used to synthesize the results from head-to-head RCTs involving Gliclazide and other oral glucose-lowering drugs. Research reported measurements of HbA1c change when studied alongside other agents in the sulfonylurea class. Some studies monitored patterns related to hypoglycemic episodes, describing a lower reported incidence of non-severe hypoglycemia when compared to certain older sulfonylureas. However, comparative evidence for Gliclazide against many newer classes of diabetes treatments remains limited.

Key Studies & References

  1. TGA. AusPAR Gliclazide
  2. Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation - ADVANCE - American College of Cardiology
  3. ADVANCE: Intensive Glucose Control Demonstrates Reduction in Vascular Events in Patients with Type 2 Diabetes
  4. Systematic Review and Meta-Analysis of The Efficacy and Hypoglycemic Safety of Gliclazide Versus Other Sulfonylureas

Frequently Asked Questions (FAQ)

Common questions about Diaprel (FAQ)


Q: What if I forget to take my Diaprel dose?

If you miss a dose, official administration guidelines advise against taking a double dose the next day to compensate. Instead, the next dose should be taken at its regularly scheduled time. Consultation with a healthcare provider is recommended before making any changes to a prescribed treatment schedule.


Q: Can Diaprel cause low blood sugar, and what are the signs?

Yes, low blood sugar, known as hypoglycemia, is classified as a common adverse reaction in official product information. Regulatory documents describe symptoms that may include sweating, trembling, dizziness, or increased hunger. Awareness of these symptoms is part of managing treatment with this medication.


Q: What happens if Diaprel is taken with alcohol?

The co-administration with alcohol is noted in regulatory information as not recommended. This is because alcohol can increase the risk of severe hypoglycemia (very low blood sugar), potentially leading to serious complications by interfering with the body's natural mechanisms for managing low sugar levels.


Q: What are the main differences between Diaprel and Diaprel MR?

Diaprel is the brand name for the medicine containing gliclazide. The MR stands for Modified Release, which is a special tablet formulation. The MR version is engineered for a slower, controlled release of the medicine, which allows for once-daily administration, unlike a standard immediate-release formulation.


Q: Why is it important to check blood sugar regularly while on Diaprel?

Because the purpose of Diaprel is to lower blood sugar, regular monitoring is necessary to ensure your glucose levels stay within the range defined by your treatment plan. Regular blood sugar monitoring may assist in keeping glucose levels within the target range and observing for symptoms of low blood sugar.


Q: What is the difference in purpose between Diaprel and insulin?

Diaprel's primary function is as an insulin secretagogue. This means it works by stimulating the pancreas to release more of your body's own natural insulin. Administered insulin, on the other hand, is a substance given to replace or supplement your body's natural supply.


Q: Is Diaprel the same type of medicine as metformin?

No. Although both are used for managing Type 2 Diabetes, Diaprel (Gliclazide) belongs to the sulfonylurea class of medicines, which work by stimulating insulin release. Metformin belongs to the biguanide class, which works through a different mechanism than sulfonylureas to manage blood sugar.


Q: How quickly should I expect Diaprel to start working?

The medicine starts to act on the body shortly after you take it. Pharmacokinetic data indicates it reaches its maximum concentration in the blood within several hours. Overall effects on long-term blood sugar control are assessed based on continuous use over several weeks.


Q: Does Diaprel have an instant effect or does it build up over time?

Diaprel begins its intended action on insulin release quickly, but it is defined in regulatory documents as a long-term treatment plan for Type 2 Diabetes. Its impact on long-term blood sugar control is assessed by monitoring biomarkers like HbA1c (blood sugar average) over a period of weeks and months.


Q: Is Diaprel known to cause weight gain or weight loss?

Clinical studies associated with the drug's regulatory profile indicate that body weight typically remains stable with gliclazide treatment. This observation describes the general pattern reported for gliclazide when studied for this outcome.


Q: Are there any long-term side effects of taking Diaprel?

Official safety information classifies adverse reactions based on frequency, which apply throughout the duration of treatment. The most frequent event is low blood sugar (hypoglycemia), while other rare but serious effects like changes in blood cell counts are also noted over the course of treatment.


Q: Is it common to feel dizzy or lightheaded when taking Diaprel?

Dizziness is listed as an adverse event in some patient information leaflets. This feeling is frequently linked to low blood sugar (hypoglycemia), which is the most common side effect of Diaprel.


Q: Does Diaprel interact with thyroid medication?

Regulatory safety information indicates that thyroid medications can potentially interfere with the regulation of blood sugar. If you are taking thyroid medicine, your prescriber may require additional monitoring and potential adjustment of your Diaprel dose.


Q: Can I take Diaprel if I am trying to conceive?

Official information advises speaking with a healthcare professional before taking the medicine if you are planning to conceive. The medicine is not recommended for use in women who are pregnant or breastfeeding.

--UNSAFE PHRASE REPORT

Q: Are there specific foods or supplements that interact with Diaprel?

Regulatory information explicitly cautions against consuming alcohol and using the herbal product St. John's Wort. The use of these substances may alter the effectiveness of Diaprel, potentially leading to low blood sugar or loss of control.


Q: Why do some people switch from one sulfonylurea to Diaprel?

Regulatory documents include procedures for switching patients from other oral hypoglycemic agents, including those from the same sulfonylurea class. This process requires careful clinical monitoring and may be done to achieve optimal blood sugar control or manage tolerability.


Q: Is Diaprel a daily medication, or can it be stopped once blood sugar is normal?

Diaprel is prescribed as part of a long-term treatment plan for Type 2 Diabetes, which is usually a chronic condition. Official guidance indicates that treatment should not be stopped without professional consultation.


Q: Does Diaprel make you feel hungry?

Feeling increased hunger is a known symptom associated with low blood sugar (hypoglycemia). Since hypoglycemia is the most frequent side effect of Diaprel, increased hunger can be an indication of blood sugar levels being too low.


Q: Does Diaprel have a maximum duration of use mentioned in official sources?

Treatment for Type 2 Diabetes is generally considered a long-term treatment plan. Official product information and regulatory guidelines do not list a maximum duration of use for Diaprel.


Q: Is there a generic version of Diaprel available?

Diaprel is a brand name for the active ingredient Gliclazide. Gliclazide is the generic name, and generic versions of the tablet are widely available from various manufacturers, depending on the region.


Q: Is it normal to have mild stomach upset when first starting Diaprel?

Gastrointestinal disorders, such as mild stomach upset, nausea, and vomiting, are classified as Uncommon adverse reactions in official safety information. These effects are sometimes observed early in treatment. The official administration advice is to take the tablet at breakfast time (with food).


Q: Does taking Diaprel affect the results of other medical tests?

Rare adverse reactions noted in regulatory documents include changes in haematology, which refers to blood cell counts (e.g., platelet levels). These changes are typically noted as being reversed once treatment is discontinued.


Q: Is there evidence that Diaprel can help prevent long-term complications of diabetes?

Large clinical trials, such as the ADVANCE trial, were conducted to monitor the effects of an intensive glucose control strategy (using Gliclazide MR as the core drug) on the frequency of major microvascular and macrovascular events (long-term complications) in patients with Type 2 Diabetes.


Q: Can I take Diaprel if I have an allergy to sulfa drugs?

Regulatory contraindications indicate that the medicine should not be used in cases of known hypersensitivity to gliclazide, other sulfonylureas, or sulfonamides. Sulfonamides are a specific chemical group related to the medicine's structure.


Q: How does Diaprel affect the pancreas?

Diaprel's core function is to act on the beta-cells within the pancreas. It stimulates these cells to release more of the body's natural insulin into the bloodstream, which is the mechanism used to help lower blood glucose levels.


Q: Do studies suggest Diaprel is better or worse for blood sugar control than other medicines?

Research has been conducted to compare Diaprel with other oral glucose-lowering drugs, specifically those in the same sulfonylurea class. These studies typically monitored patterns related to blood sugar control, such as changes in the HbA1c marker.


Q: Can Diaprel cause changes in vision?

Patient information indicates that vision may be affected for a short time, particularly when first starting treatment. This is often an effect linked to the initial changes in blood sugar levels rather than a direct action of the drug on the eyes.


Q: Is Diaprel often prescribed for prediabetes?

Official prescribing information defines the authorized use of Diaprel for the management of Type 2 Diabetes Mellitus in adults. The authorized use is strictly defined for the management of Type 2 Diabetes Mellitus, not for prediabetes.


Q: Are there specific warnings about driving or operating machinery while on Diaprel?

Regulatory guidance advises that if low blood sugar (hypoglycemia) occurs, which can affect concentration, driving or operating machinery should be avoided. This warning is in place because the risk of low blood sugar can impair concentration and reaction time.


Q: Can Diaprel cause sensitivity to sunlight?

Some patient information notes that this medication may increase the skin's sensitivity to the sun or sun lamps (photosensitivity). This indication suggests that precautions against excessive sun exposure may be warranted.


Q: What should I do if I notice unusual bruising while taking Diaprel?

Unusual bruising may be a sign of a rare but serious adverse reaction involving a decrease in the number of blood components, such as platelets ( haematological disorders). Regulatory guidance notes that these symptoms typically vanish when treatment is discontinued.


Q: How long does it take for Diaprel's effects to wear off after stopping?

Pharmacokinetic data provides information on how long the substance stays in the body. The apparent terminal elimination half-life for the active ingredient, gliclazide, is described as being approximately 20 hours in humans.


Q: Is it mandatory to monitor liver function while taking Diaprel?

Rare adverse reactions include elevated hepatic enzyme levels and liver disease. While severe liver impairment is a contraindication, regulatory information suggests that monitoring is necessary for those with mild to moderate liver impairment to ensure patient safety.


Q: What is the half-life of Diaprel?

The apparent terminal elimination half-life for the active ingredient, gliclazide, is described in pharmacokinetic data as approximately 20 hours. The half-life refers to the time it takes for half of the substance to be removed from the body.

How should Diaprel be stored and disposed of?

Diaprel (Gliclazide) must be stored according to specific conditions defined in regulatory product labeling to ensure its stability.

Storage Requirements

Category Official Constraint
Temperature Range Do not store above 25 C or 30 C, depending on the formulation. Some documents state no special storage conditions are required.
Handling/Protection Do not freeze the medicine. It must be protected from moisture and direct sunlight.
Child Safety Keep out of the sight and reach of children to prevent accidental ingestion.

Disposal Instructions

Any unused medicinal product or waste material must be disposed of in accordance with local requirements and should not be discarded into household waste or wastewater. Expired medicine should be returned to a pharmacist for appropriate disposal.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Diaprel found in:

A-Z Index: